PRMT5 Inhibition Drives Therapeutic Vulnerability to BCL-2 Inhibition with Venetoclax and Provides Rationale for Combination Therapy in Mantle Cell Lymphoma

被引：4
|
作者：
Brown, Fiona [1 ]
Zhang, Yang [2 ]
Hinterschied, Claire [1 ]
Prouty, Alexander [1 ]
Sloan, Shelby [3 ]
Helmig-Mason, JoBeth [3 ]
Chung, Ji Hyun [1 ]
Vaddi, Kris [2 ]
Chen-Kiang, Selina [4 ]
Di Liberto, Maurizio [4 ]
Alinari, Lapo [1 ]
Scherle, Peggy [2 ]
Lapalombella, Rosa [3 ]
Paik, Jihye [5 ]
Baiocchi, Robert A. [6 ]
机构：
[1] Ohio State Univ, Div Hematol, Dept Internal Med, Coll Med, Columbus, OH USA
[2] Prelude Therapeut, Wilmington, DE USA
[3] Ohio State Univ, Div Hematol, Dept Internal Med, Columbus, OH USA
[4] Weill Cornell Med Coll, Dept Pathol & Lab Med, New York, NY USA
[5] Cornell Univ, Paik Lab, New York, NY 10021 USA
[6] Ohio State Univ, James Comprehens Canc Ctr, Columbus, OH 43210 USA
来源：
BLOOD | 2019年 / 134卷
关键词：
D O I：
10.1182/blood-2019-130797
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
302
引用
收藏
页数：4
相关论文
共 50 条
  • [21] High efficacy of the BCL-2 inhibitor ABT199 (venetoclax) in BCL-2 high-expressing neuroblastoma cell lines and xenografts and rational for combination with MCL-1 inhibition
    Bate-Eya, Laurel T.
    den Hartog, Ilona J. M.
    van der Ploeg, Ida
    Schild, Linda
    Koster, Jan
    Santo, Evan E.
    Westerhout, Ellen M.
    Versteeg, Rogier
    Caron, Huib N.
    Molenaar, Jan J.
    Dolman, M. Emmy M.
    ONCOTARGET, 2016, 7 (19) : 27946 - 27958
  • [22] Combination BCL-2 Inhibitor Therapy with Venetoclax and Navitoclax in Patients with Relapsed/Refractory Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma
    Jabbour, Elias
    Mullighan, Charles G.
    Pullarkat, Vinod A.
    Lacayo, Norman J.
    Bajel, Ashish
    Rubnitz, Jeffrey
    Leonard, Jessica
    Khaw, Seong Lin
    Vear, Susan I.
    Alexander, Thomas
    Norris, Robin
    Salem, Ahmed
    Schmidt, Michelle
    Tong, Bo
    Zhou, Ying
    Ross, Jeremy A.
    Bensman, Lindsey
    Jacobson, Amanda
    Stock, Wendy
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2019, 19 : S184 - S185
  • [23] Dual Targeting Bcl-2 By Venetoclax and Mcl-1 By AZD5991 to Overcome Therapeutic Resistance in Aggressive R/R Mantle Cell Lymphoma
    Li, Yijing
    Liu, Yang
    Che, Yuxuan
    Jordan, Alexa A.
    McIntosh, Joseph
    Leeming, Angela
    Andersen, Courtney L.
    Cidado, Justin
    Jin, Jingling
    Jiang, Vivian Changying
    Wang, Michael
    BLOOD, 2021, 138
  • [24] PRMT5 Inhibition Modulates E2F1 and P53 to Restore Cell Cycle Regulation and Drive DNA Damage Response in Ibrutinib-Resistant Mantle Cell Lymphoma
    Sloan, Shelby
    Brown, Fiona
    Long, Mackenzie
    Helmig-Mason, JoBeth
    Beck, Stacey
    Chung, Ji Hyun
    Hanel, Walter
    Brooks, Eric
    Klimazewski, Haley
    Meydan, Cem
    Foox, Jonathan
    Butler, Daniel
    Byrd, John C.
    Lapalombella, Rosa
    Di Liberto, Maurizio
    Mason, Christopher
    Chen-Kiang, Selina
    Vaddi, Kris
    Scherle, Peggy
    Baiocchi, Robert
    Alinari, Lapo
    BLOOD, 2021, 138
  • [25] Combination Therapy of Bcl-2/X L dual Inhibitor AZD0466 with Acalabrutinib to Overcome Therapeutic Resistance in Aggressive R/R Mantle Cell Lymphoma
    Li, Yijing
    Liu, Yang
    Che, Yuxuan
    McIntosh, Joseph
    Jordan, Alexa A.
    Leeming, Angela
    Andersen, Courtney L.
    Cidado, Justin
    Jin, Jingling
    Jiang, Vivian Changying
    Wang, Michael
    BLOOD, 2021, 138 : 1867 - +
  • [26] Inhibition of casein kinase 2 sensitizes mantle cell lymphoma to venetoclax through MCL-1 downregulation
    Thus, Yvonne J.
    de Rooij, Martin F. M.
    Swier, Nathalie
    Beijersbergen, Roderick L.
    Guikema, Jeroen E. J.
    Kersten, Marie-Jose
    Eldering, Eric
    Pals, Steven T.
    Kater, Arnon P.
    Spaargaren, Marcel
    HAEMATOLOGICA, 2023, 108 (03) : 797 - 810
  • [27] PROTEIN KINASE CK2 INHIBITION IN MANTLE CELL LYMPHOMA SYNERGICALLY POTENTIATES VENETOCLAX INDUCED CYTOTOXICITY
    Manni, S.
    Spinello, Z.
    Pesavento, M.
    Fregnani, A.
    Saggin, L.
    Tubi, L. Quotti
    Semenzato, G.
    Trentin, L.
    Piazza, F.
    HAEMATOLOGICA, 2022, 107 : 78 - 78
  • [28] Potent combination benefit of the AKT inhibitor capivasertib and the BCL-2 inhibitor venetoclax in diffuse large B cell lymphoma
    Willis, Brandon S.
    Mongeon, Kevin
    Dry, Hannah
    Neveras, India L.
    Bryan, Nadezda
    Pandya, Meghana
    Roderick-Richardson, Justine
    Xu, Wendan
    Yang, Li
    Rosen, Alan
    Reimer, Corinne
    Tuskova, Liliana
    Klener, Pavel
    Mettetal, Jerome T.
    Lenz, Georg
    Barry, Simon T.
    LEUKEMIA, 2024, 38 (12) : 2663 - 2674
  • [29] Expanded T-cell clones in CLL persist during combination therapy with BCL-2 inhibitor Venetoclax
    Maass, C.
    Schilhabel, A.
    Chall, P.
    Al-Sawaf, O.
    Tausch, E.
    Darzentas, N.
    Stilgenbauer, S.
    Fischer, K.
    Eichhorst, B.
    Baldus, C. D.
    Hallek, M.
    Bruggemann, M.
    Ritgen, M.
    ONCOLOGY RESEARCH AND TREATMENT, 2023, 46 : 36 - 36
  • [30] Aurora kinase B inhibition in small-cell lung cancer: BCL-2 as a potential therapeutic biomarker and combination target
    Hosoya, Kazutaka
    Ozasa, Hiroaki
    TRANSLATIONAL LUNG CANCER RESEARCH, 2024, 13 (03) : 689 - 693
12345